Actively Recruiting // Barbara Blodi // Clinical Trials // Macular Telangiectasia // Other // Dec 01 2020
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (Mac Tel)
- Sponsor: Neurotech Pharmaceuticals, Inc.
- Principal Investigator: Barbara Blodi, MD
- Study Coordinator: Kris Dietzman
Study objective:
To evaluate long term safety and efficacy of the NT-501 implant in participants that previously enrolled in the NTMT-01 and NTMT-02 protocols.
Study design:
The study will include one visit per year over a 4-year period.
Inclusion criteria:
- Previously enrolled in the NTMT-01 or NTMT-02 protocol and received the NT-501 implant and/or underwent a Sham procedure
Exclusion criteria:
- None
Contact Kris Dietzman with questions, 608-263-9035
For more information about this study, visit clinicaltrials.gov.